104 related articles for article (PubMed ID: 15497751)
21. Dry powder inhalers: the influence of device resistance and powder formulation on drug and lactose deposition in vitro.
Srichana T; Martin GP; Marriott C
Eur J Pharm Sci; 1998 Dec; 7(1):73-80. PubMed ID: 9845780
[TBL] [Abstract][Full Text] [Related]
22. Development of a laser diffraction method for the determination of the particle size of aerosolised powder formulations.
Marriott C; MacRitchie HB; Zeng XM; Martin GP
Int J Pharm; 2006 Dec; 326(1-2):39-49. PubMed ID: 16942848
[TBL] [Abstract][Full Text] [Related]
23. Physicochemical and in vitro deposition properties of salbutamol sulphate/ipratropium bromide and salbutamol sulphate/excipient spray dried mixtures for use in dry powder inhalers.
Corrigan DO; Corrigan OI; Healy AM
Int J Pharm; 2006 Sep; 322(1-2):22-30. PubMed ID: 16815654
[TBL] [Abstract][Full Text] [Related]
24. Liposomal amphotericin B dry powder inhaler: effect of fines on in vitro performance.
Shah SP; Misra A
Pharmazie; 2004 Oct; 59(10):812-3. PubMed ID: 15544064
[TBL] [Abstract][Full Text] [Related]
25. Novel Budesonide Particles for Dry Powder Inhalation Prepared Using a Microfluidic Reactor Coupled With Ultrasonic Spray Freeze Drying.
Saboti D; Maver U; Chan HK; Planinšek O
J Pharm Sci; 2017 Jul; 106(7):1881-1888. PubMed ID: 28285981
[TBL] [Abstract][Full Text] [Related]
26. SCF-engineered powders for delivery of budesonide from passive DPI devices.
Lobo JM; Schiavone H; Palakodaty S; York P; Clark A; Tzannis ST
J Pharm Sci; 2005 Oct; 94(10):2276-88. PubMed ID: 16136557
[TBL] [Abstract][Full Text] [Related]
27. The influence of dose on the performance of dry powder inhalation systems.
Young PM; Edge S; Traini D; Jones MD; Price R; El-Sabawi D; Urry C; Smith C
Int J Pharm; 2005 May; 296(1-2):26-33. PubMed ID: 15885452
[TBL] [Abstract][Full Text] [Related]
28. The effect of budesonide particle mass on drug particle detachment from carrier crystals in adhesive mixtures during inhalation.
Dickhoff BH; Ellison MJ; de Boer AH; Frijlink HW
Eur J Pharm Biopharm; 2002 Sep; 54(2):245-8. PubMed ID: 12191698
[TBL] [Abstract][Full Text] [Related]
29. Delivery of formoterol from a novel multi-dose inhaler Airmax.
Zeng XM; Jones S; O'Leary D; Phelan M; Colledge J
Respir Med; 2002 Jun; 96(6):397-403. PubMed ID: 12117038
[TBL] [Abstract][Full Text] [Related]
30. The Novolizer: a multidose dry powder inhaler.
Siddiqui MA; Plosker GL
Treat Respir Med; 2005; 4(1):63-9. PubMed ID: 15725051
[TBL] [Abstract][Full Text] [Related]
31. Effects of mild processing pressures on the performance of dry powder inhaler formulations for inhalation therapy. 1: Budesonide and lactose.
Marek SR; Donovan MJ; Smyth HD
Eur J Pharm Biopharm; 2011 May; 78(1):97-106. PubMed ID: 21182942
[TBL] [Abstract][Full Text] [Related]
32. Idealhalers or realhalers? A comparison of Diskus and Turbuhaler.
Borgström L; Asking L; Thorsson L
Int J Clin Pract; 2005 Dec; 59(12):1488-95. PubMed ID: 16351685
[TBL] [Abstract][Full Text] [Related]
33. Adhesion forces in interactive mixtures for dry powder inhalers--evaluation of a new measuring method.
Lohrmann M; Kappl M; Butt HJ; Urbanetz NA; Lippold BC
Eur J Pharm Biopharm; 2007 Sep; 67(2):579-86. PubMed ID: 17418548
[TBL] [Abstract][Full Text] [Related]
34. Scintigraphic evaluation of lung deposition with a novel inhaler device.
Newman SP; Hirst PH; Pitcairn GR
Curr Opin Pulm Med; 2001 Apr; 7 Suppl 1():S12-4. PubMed ID: 11385810
[TBL] [Abstract][Full Text] [Related]
35. Effect of particle morphology on the triboelectrification in dry powder inhalers.
Murtomaa M; Mellin V; Harjunen P; Lankinen T; Laine E; Lehto VP
Int J Pharm; 2004 Sep; 282(1-2):107-14. PubMed ID: 15336386
[TBL] [Abstract][Full Text] [Related]
36. Preparation and in vitro evaluation of lipidic carriers and fillers for inhalation.
Sebti T; Amighi K
Eur J Pharm Biopharm; 2006 May; 63(1):51-8. PubMed ID: 16380243
[TBL] [Abstract][Full Text] [Related]
37. A 12-week, multicenter, randomized, partially blinded, active-controlled, parallel-group study of budesonide inhalation suspension in adolescents and adults with moderate to severe persistent asthma previously receiving inhaled corticosteroids with a metered-dose or dry powder inhaler.
Murphy K; Noonan M; Silkoff PE; Uryniak T
Clin Ther; 2007 Jun; 29(6):1013-26. PubMed ID: 17692718
[TBL] [Abstract][Full Text] [Related]
38. Drug delivery to the lungs from dry powder inhalers.
Newman SP
Curr Opin Pulm Med; 2003 Apr; 9 Suppl 1():S17-20. PubMed ID: 12974538
[TBL] [Abstract][Full Text] [Related]
39. The influence of carrier roughness on adhesion, content uniformity and the in vitro deposition of terbutaline sulphate from dry powder inhalers.
Flament MP; Leterme P; Gayot A
Int J Pharm; 2004 May; 275(1-2):201-9. PubMed ID: 15081150
[TBL] [Abstract][Full Text] [Related]
40. Experimental observations of dry powder inhaler dose fluidisation.
Tuley R; Shrimpton J; Jones MD; Price R; Palmer M; Prime D
Int J Pharm; 2008 Jun; 358(1-2):238-47. PubMed ID: 18457930
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
